Literature DB >> 7819584

The p53 tumor suppressor gene in breast cancer.

R M Elledge1, D C Allred.   

Abstract

Alterations of the p53 tumor suppressor gene are the most common genetic changes found so far in breast cancer, suggesting that the gene plays a central role in the development of the disease. p53 functions as a negative regulator of cell growth, and alterations in the gene lead to loss of this negative growth regulation and more rapid cell proliferation. A number of independent groups using different methods of detection have shown that p53 alterations are associated with more aggressive tumor biologic factors and a poorer prognosis in breast cancer patients. Because of its possible role in the regulation of apoptosis and response to DNA damage, p53 status could also be a predictive marker for response to hormonal or chemotherapy.

Entities:  

Mesh:

Year:  1994        PMID: 7819584     DOI: 10.1007/bf00666204

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  51 in total

1.  The gene for the rat heat-shock cognate, hsc70, can suppress oncogene-mediated transformation.

Authors:  F Yehiely; M Oren
Journal:  Cell Growth Differ       Date:  1992-11

2.  Expression of the normal p53 gene induces differentiation of K562 cells.

Authors:  E Feinstein; R P Gale; J Reed; E Canaani
Journal:  Oncogene       Date:  1992-09       Impact factor: 9.867

3.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

4.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

5.  p53 alterations in all stages of breast cancer.

Authors:  A M Davidoff; B J Kerns; J C Pence; J R Marks; J D Iglehart
Journal:  J Surg Oncol       Date:  1991-12       Impact factor: 3.454

6.  Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: influence on metastasis-free survival.

Authors:  E Hanzal; G Gitsch; P Kohlberger; C Dadak; N Miechowiecka; G Breitenecker
Journal:  Anticancer Res       Date:  1992 Nov-Dec       Impact factor: 2.480

7.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

8.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

9.  Wild-type p53 binds to the TATA-binding protein and represses transcription.

Authors:  E Seto; A Usheva; G P Zambetti; J Momand; N Horikoshi; R Weinmann; A J Levine; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

Authors:  N Kyprianou; H F English; N E Davidson; J T Isaacs
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

View more
  26 in total

1.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

2.  Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.

Authors:  G Wani; I Noyes; G E Milo; S M D'Ambrosio
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

Review 3.  Interrogating mouse mammary cancer models: insights from gene expression profiling.

Authors:  Antonio A Fargiano; Kartiki V Desai; Jeffrey E Green
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

4.  Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline based chemotherapy.

Authors:  Laura M Vargas-Roig; F Darío Cuello-Carrión; Nicolás Fernández-Escobar; Pedro Daguerre; Marcela Leuzzi; Jorge Ibarra; Francisco E Gago; Silvina B Nadin; Daniel R Ciocca
Journal:  Mol Oncol       Date:  2008-01-13       Impact factor: 6.603

5.  Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast.

Authors:  G P Howes; J Stephenson; S Humphreys
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

6.  FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.

Authors:  W R Xing; K W Gilchrist; C P Harris; W Samson; L F Meisner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

Review 8.  Biological features of premalignant disease in the human breast.

Authors:  D C Allred; S K Mohsin
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

9.  Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.

Authors:  Luciane R Cavalli; Rebecca B Riggins; Antai Wang; Robert Clarke; Bassem R Haddad
Journal:  Breast Cancer Res Treat       Date:  2009-08-21       Impact factor: 4.872

10.  Detection of P53 mutations in different cancer types is improved by cDNA sequencing.

Authors:  Sylwester Piaskowski; Izabela Zawlik; Malgorzata Szybka; Dominika Kulczycka-Wojdala; Ewelina Stoczynska-Fidelus; Michal Bienkowski; Tadeusz Robak; Renata Kusinska; Dorota Jesionek-Kupnicka; Radzislaw Kordek; Piotr Rieske; Pawel P Liberski
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.